Screener
Wave Life Sciences WVE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
FAQ
- What is Wave Life Sciences's cash & equivalents?
- Wave Life Sciences (WVE) reported cash & equivalents of $368.01M in Q2 2026.
- How has Wave Life Sciences's cash & equivalents changed year-over-year?
- Wave Life Sciences's cash & equivalents increased by 76.5% year-over-year, from $208.48M to $368.01M.
- What is the long-term trend for Wave Life Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), Wave Life Sciences's cash & equivalents has grown at a 26.7% compound annual growth rate (CAGR), from $184.5M to $602.07M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Wave Life Sciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude